



10 / 506934  
PCT/EP 03 / 02698



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

EPO - DG 1

31.03.2003



REC'D 09 APR 2003

WIPO PCT


08 SEP 2004

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*P. Mahoney*

Dated 14 March 2003

**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

**BEST AVAILABLE COPY**



The  
**Patent  
Office**

PCT/EP 03 / 02698

**1/77**

**Request for grant of a patent**

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office  
Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference

TC/DAB/PG4771

2. Patent application number

(The Patent Office will fill in his part)

**0206200.8**

18MAR02 E704079-1 C69803  
P01/7700 0.00-0206200.8

**15 MAR 2002**

3. Full name, address and postcode of the or of each applicant (underline all surnames)

Patents ADP number (*if you know it*)

If the applicant is a corporate body, give the country/state of its incorporation

Glaxo Group Limited  
Glaxo Wellcome House, Berkeley Avenue,  
Greenford, Middlesex UB6 0NN, Great Britain

United Kingdom

**473587003**

4. Title of the invention

Pharmaceutical Compositions

5. Name of your agent (*if you have one*)

"Address for service" in the United Kingdom to which all correspondence should be sent  
(*including the postcode*)

Patents ADP number (*if you know it*)

Corporate Intellectual Property

GlaxoSmithKline  
Corporate Intellectual Property CN925.1  
980 Great West Road  
BRENTFORD  
Middlesex TW8 9GS

**7960982003**

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (*if you know it*) the or each application number

Country	Priority application number ( <i>if you know it</i> )	Date of filing ( <i>day / month / year</i> )
---------	--	---

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application	Date of filing ( <i>day / month / year</i> )
-------------------------------	---

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (*Answer yes if:*

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is named as an applicant, or
  - c) any named applicant is a corporate body
- See note (d)

# Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.  
Do not count copies of the same document

Continuation sheets of this form  
Description  
Claim(s)  
Abstract  
Drawings

11  
1  
1  
1

RW

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*)

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11.

We request the grant of a patent on the basis of this application

Signature A C Connell Date 14-Mar-02  
A C Connell

12. Name and daytime telephone number of person to contact in the United Kingdom

A C Connell 01279 644395

## Warning

*After an application for a Patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission unless an application has been filed at least six weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.*


## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- For details of the fee and ways to pay please contact the Patent Office.*

## Pharmaceutical Compositions

The present invention relates to certain novel pharmaceutical compositions comprising a selective cyclooxygenase-2 inhibitor, processes for their preparation, methods of treatment of cyclooxygenase-2 mediated diseases comprising administering such compositions to a subject, and to the use of such compositions in the manufacture of medicaments.

WO99/12930 (Glaxo Group Limited) discloses 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine (I) as a potent and selective inhibitor of cyclooxygenase-2 (COX-2).



Dissolution testing is a well established technique for obtaining a correlation between in vitro and in vivo data in relation to compound bioavailability. Preliminary dissolution experiments employing compound (I) in micronised form predicted it to be poorly bioavailable. As a result attempts were made to improve the bioavailability of compound (I). WO01/41760 (Pharmacia Corporation) discloses that the bioavailability of selective COX-2 inhibitory drugs of low water solubility may be enhanced by reducing the drug particle size, such that a substantial proportion are smaller than 1  $\mu\text{m}$ . However, dissolution experiments using a pharmaceutical composition comprising compound (I), wherein the drug was present in nanoparticulate form, still resulted in a poor dissolution profile, thus predicting this pharmaceutical composition to be poorly bioavailable in man. Further dissolution experiments indicated that the bioavailability of compound (I) could be enhanced by co-formulation with hydroxypropylmethylcellulose-acetyl succinate (HPMC-AS) in an amorphous dispersion. Moreover a 1:1 ratio of compound (I) and HPMC-AS was found to be optimal.


As a result a pharmaceutical composition comprising a 1:1 ratio of compound (I) and hydroxypropylmethylcellulose-acetyl succinate (HPMC-AS) as an amorphous dispersion has been administered to man at 35mg o.d. The resulting pharmacokinetic parameters such as the maximum blood serum concentration of the drug ( $C_{\text{max}}$ ), the time to achieve the maximum

blood serum concentration of the drug ( $T_{max}$ ) and the exposure of the volunteer to the drug as measured by the area under the plasma concentration versus time curve (AUC) were all conducive to the further development of compound (I). However, unacceptably high inter-subject variability was seen for these parameters.

5

The problem of high inter-subject variability for the parameters  $C_{max}$ ,  $T_{max}$  and AUC may be solved by providing a pharmaceutical composition comprising compound (I), wherein the drug is present in nanoparticulate form.

- 10 Accordingly, in a first aspect the invention thus provides a pharmaceutical composition comprising a compound of formula (I)



- 15 and pharmaceutically acceptable salts thereof, in which the compound is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients.

- Surprisingly, we have now found that a pharmaceutical composition as defined hereinabove results in significantly reduced inter-subject variability for both  $C_{max}$ ,  $T_{max}$  and AUC when dosed in human volunteers. Furthermore, and contrary to expectation, this pharmaceutical composition resulted in a pharmacokinetic profile in man with a shorter  $T_{max}$ , a higher  $C_{max}$  and a higher AUC in comparison with the pharmacokinetic profile for the composition comprising a 1:1 ratio of compound (I) and hydroxypropylmethylcellulose-acetyl succinate (HPMC-AS) as an amorphous dispersion. Such a pharmacokinetic profile is particularly beneficial for the treatment of acute pain disorders where early and rapid relief from the pain or other symptoms is desired.

- For the purposes of the present invention "nanoparticulate" is defined as solid particles with a median size by volume  $[D(v,0.5)]$  in the range 0.4 to 1.5  $\mu m$ .

30

In another aspect of the invention compound (I) is present in solid particles with a  $D(v,0.5)$  in the range 0.45 to 1.05  $\mu\text{m}$ .

The particle size of the solid particles of compound (I) may be determined by laser diffraction.

5 A suitable machine for determining particle size by laser diffraction is a Sympatec laser diffraction unit, using an HELOS optical bench fitted with a QUIXEL dispersion unit. As used herein, the median size by volume [ $D(v,0.5)$ ] of the particles is determined by laser diffraction, as defined above.

10 Numerous processes for the synthesis of solid particles in nanoparticulate form are known. Typically these processes involve a milling process, preferably a wet milling process in the presence of a surface modifying agent that inhibits aggregation and/or crystal growth of the nanoparticles once created. Alternatively these processes may involve a precipitation process, preferably a process of precipitation in an aqueous medium from a solution of the drug in a  
15 non-aqueous solvent.

Accordingly, in a further aspect, the present invention provides a process for preparing compound (I) in nanoparticulate form as hereinbefore defined, which process comprises milling or precipitation.

20

Representative processes for the preparation of solid particles in nanoparticulate form are described in the patents and publications listed below.

U.S. Patent No. 4,826,689 to Violanto & Fischer

U. S. Patent No. 5,145,684 to Liversidge et al

25 U.S Patent No. 5,298,262 to Na & Rajagopalan

U.S. Patent No. 5,302,401 Liversidge et al

U.S. Patent No. 5,336,507 to Na & Rajagopalan

U.S. Patent No. 5,340,564 to Illig & Sarpotdar

U.S. Patent No. 5,346,702 to Na Rajagopalan

30 U.S. Patent No. 5,352,459 to Hollister et al

U.S. Patent No. 5,354,560 to Lovrecich

U.S. Patent No. 5,384,124 to Courteille et al

U.S. Patent No. 5,429,824 to June

U.S. Patent No. 5,503,723 to Ruddy et al

35 U.S. Patent No. 5,510 118 to Bosch et al

U.S. Patent No. 5,518 to Bruno et al

U.S. Patent No. 5,518,738 to Eickhoff et al

- U.S. Patent No. 5,534,270 to De Castro
- U.S. Patent No. 5,536,508 to Canal et al
- U.S. Patent No. 5,552,160 to Liversidge et al
- U.S. Patent No. 5,560,931 to Eickhoff et al
- 5 U.S. Patent No. 5,560,932 to Bagchi et al
- U.S. Patent No. 5,565,188 to Wong et al
- U.S. Patent No. 5,571,536 to Eickhoff et al
- U.S. Patent No. 5,573,783 to Desieno & Stetsko
- U.S. Patent No. 5,580,579 to Ruddy et al
- 10 U.S. Patent No 5,585,108 to Ruddy et al
- U.S. Patent No. 5,587,143 to Wong
- U.S. Patent No. 5,591,456 to Franson et al
- U.S. Patent No. 5,622,938 to Wong
- U.S. Patent No 5,662,883 to Bagchi et al
- 15 U.S. Patent No. 5,665,331 to Bagchi et al
- U.S. Patent No. 5,718,919 to Ruddy et al
- U.S. Patent No. 5,747,001 to Wiedmann et al
- International Patent Publication No WO93/25190
- International Patent Publication No. WO96/24336
- 20 International Patent Publication No. WO 97/14407
- International Patent Publication No. WO 98/35666
- International Patent Publication No. WO 99/65469
- International Patent Publication No. WO 00/18374
- International Patent Publication No. WO 00/27369
- 25 International Patent Publication No. WO 00/30615 and
- International Patent Publication No. WO 01/41760.

Such processes may be readily adapted for the preparation of compound (I) in nanoparticulate form. Such processes form a further aspect of the invention.

30

The process of the present invention preferably uses a wet milling step carried out in a mill such as a dispersion mill in order to produce a nanoparticulate form of the compound. The present invention may be put into practice using a conventional wet milling technique, such as that described in Lachman *et al.*, The Theory and Practice of Industrial Pharmacy, Chapter 2,

35 "Milling" p.45 (1986).

In a further refinement, PCT/EP01/07085 (SmithKline Beecham plc) describes a wet milling procedure using a mill, in which at least some of the surfaces are made of nylon (polyamide) comprising one or more internal lubricants, for use in the preparation of solid particles of a drug substance in nanoparticulate form.

5

In another aspect the present invention provides a process for preparing compound (I) in nanoparticulate form comprising wet milling a suspension of compound (I) in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising a lubricated nylon, as described in PCT/EP01/07085.

10

The suspension of compound (I) for use in the wet milling is typically a liquid suspension of the coarse compound in a liquid medium. By "suspension" is meant that the compound is essentially insoluble in the liquid medium. Representative liquid media include an aqueous medium. Using the process of the present invention the average particle size of coarse compound (I) may be up to 1mm in diameter. This advantageously avoids the need to pre-process the compound.

15

In a further aspect of the invention the aqueous medium to be subjected to the milling comprises compound (I) present in from about 1% to about 40% w/w, preferably from about 10% to about 30% w/w, more preferably about 20% w/w.

20

The aqueous medium may further comprise one or more pharmaceutically acceptable water-soluble carriers which are suitable for steric stabilisation and the subsequent processing of compound (I) after milling to a pharmaceutical composition, e.g. by spray drying.

25

Pharmaceutically acceptable excipients most suitable for steric stabilisation and spray-drying are surfactants such as poloxamers, sodium lauryl sulphate and polysorbates etc; stabilisers such as celluloses e.g. hydroxypropylmethyl cellulose; and carriers such as carbohydrates e.g. mannitol.

30

In a further aspect of the invention the aqueous medium to be subjected to the milling may further comprise hydroxypropylmethyl cellulose (HPMC) present in from about 0.1 to about 10% w/w, preferably in about 5% w/w in the aqueous medium to be subjected to the milling.

35

In a further aspect of the invention the aqueous medium to be subjected to the milling may further comprise mannitol present in from about 1 to about 15% w/w, preferably in about 10% w/w, in the aqueous medium to be subjected to the milling.

The process of the present invention may comprise the subsequent step of drying compound (I) to yield a powder.



Accordingly, in a further aspect, the present invention provides a process for preparing a pharmaceutical composition as hereinbefore defined, which process comprises producing compound (I) in nanoparticulate form optionally followed by drying to yield a powder.

5

By "drying" is meant the removal of any water or other liquid vehicle used during the process to keep compound (I) in liquid suspension or solution. This drying step may be any process for drying known in the art, including freeze drying, spray granulation or spray drying. Of these methods spray drying is particularly preferred. All of these techniques are well known in the art.

10

Spray drying/fluid bed granulation of milled compositions is carried out most suitably using a spray dryer such as a Mobile Minor Spray Dryer [Niro, Denmark], or a fluid bed drier, such as those manufactured by Glatt, Germany.

15

In a further aspect the invention provides a pharmaceutical composition as hereinbefore defined, in the form of a dried powder, obtainable by wet milling solid particles of compound (I) followed by spray-drying the resultant suspension.

20

Preferably, the pharmaceutical composition as hereinbefore defined, further comprises HPMC present in less than 15% w/w, preferably in the range 0.1 to 10% w/w, more preferably in about 5% w/w.

25

Preferably the pharmaceutical composition as hereinbefore defined, in the form of a dried powder, further comprises mannitol present in less than 30% w/w, preferably in the range 1 to 15% w/w, more preferably in about 10% w/w.

30

Preferably the pharmaceutical composition as hereinbefore defined, in the form of a dried powder, further comprises HPMC present in less than 15% w/w, preferably in the range 0.1 to 10% w/w, and mannitol present in less than 30% w/w, preferably in the range 1 to 15% w/w.

35

The solid particles of compound (I) obtainable by wet milling, optionally followed by the step of spray-drying, according to the present invention, may be presented in a variety of finished formulations including, for instance, tablets, for example swallow tablets, dispersible tablets and chewable tablets; in capsules; aqueous syrups and sachets. These may be prepared by combining the pharmaceutical composition of the present invention with excipients conventionally used in such formulations such as disintegrants, diluents, lubricants, wetting agents, binding agents, flavoring agents, sweeteners, colouring agents, preservatives, suspending agents, coating agents and fillers, and further processing into finished formulations.

Thus, in a further aspect, pharmaceutical formulations of the present invention comprise pharmaceutical compositions as hereinbefore defined, optionally together with one or more excipients such as disintegrants, diluents, lubricants, wetting agents, binding agents, flavoring agents, sweeteners, colouring agents, preservatives, suspending agents, coating agents and fillers.

Representative disintegrants for use in the instant invention illustratively include maize-starch and rice starch, cross-linked N-vinyl-2-pyrrolidinone, sodium starch glycolate, croscarmellose sodium, microcrystalline or microfine cellulose, low substituted hydroxypropylcellulose (i.e. cellulose partially substituted with 2-hydroxypropyl groups e.g. less than 25% substituted) cross-linked sodium carboxymethylcellulose, swellable ion exchange resins, formaldehyde-casein or alignates.

Representative lubricants for use in the instant invention illustratively include a long chain fatty acid, such as stearic acid, or salts thereof, such as magnesium stearate.

Representative fillers for use in the instant invention illustratively include silicon dioxide, microcrystalline cellulose, dicalcium phosphate, lactose, sorbitol, calcium carbonate or magnesium carbonate.

In another aspect the invention provides a pharmaceutical composition comprising compound (I) in a form which results in a pharmacokinetic profile in a healthy male volunteer study wherein the median  $T_{max}$  is in the range 0.75 to 1.25 hours, the median  $C_{max}$  is in the range 130 to 170 ng/mL and the AUC (last) is in the range 800 to 900 ng/mL.h.

In another aspect the invention is directed to a method of treating a human or animal subject suffering from a condition which is mediated by selective inhibition of COX-2 which comprises administering a pharmaceutical composition comprising compound formula (I) or a pharmaceutically acceptable salt thereof in which the compound is present in solid particles in nanoparticulate form.

In another aspect the invention is directed to the use of a pharmaceutical composition comprising compound (I) or a pharmaceutically acceptable salt thereof in which the compound is present in solid particles in nanoparticulate form for the manufacture of a medicament for the treatment of a condition which is mediated by selective inhibition of COX-2.

All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth.

5

The example that follows illustrates the invention but does not limit the invention in any way.

#### Example 1 (Pharmaceutical Composition 2)

10 A 1 kg batch of an aqueous suspension containing 20% w/w of 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine and 5% w/w of hydroxypropylmethylcellulose was passed through a Dena DM-100 bead mill. The single 100ml chamber fabricated from Nylacast Nylube was used in a recirculation configuration with the chamber containing 85% by volume of yttrium stabilised zirconium oxide beads (Tosoh, Japan). The batch was processed using four different bead sizes in sequence: 1mm diameter bead sample, 0.65mm diameter  
15 bead sample, 0.4mm diameter bead sample, 0.3mm diameter bead sample. The batch was processed for one hour using each bead sample. The yield was 81.3%. To the finely milled suspension was added 10% w/w mannitol and the resulting suspension subsequently spray-dried to yield Pharmaceutical Composition 2.

20 Grinding media contamination levels in the spray-dried powder (Pharmaceutical Composition 2) were 7ppm zirconium (Zr) and <1ppm yttrium (Y).

The product had a median particle size of 1.01 microns as measured by laser diffraction size analysis using a Sympatec laser diffraction unit, with a HELOS optical bench fitted with a  
25 QUIXEL dispersion unit.

#### Study 1

A randomised, open label, crossover comparison between single oral doses of 35mg of each of two pharmaceutical compositions of 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-  
30 pyrazolo[1,5-b]pyridazine was conducted in 24 healthy male volunteers. Single oral doses of 35mg of each of two pharmaceutical compositions of 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine were administered to fasted volunteers. Seven day intervals separated each dose. The pharmacokinetic characteristics of each pharmaceutical composition were determined over a 48 hour time period.

35 Pharmaceutical Composition 1 – Amorphous spray-dried pharmaceutical composition comprising 2-(4-ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine and

hydroxypropylmethylcellulose-acetyl succinate in a 1:1 ratio produced by conventional spray-drying techniques.

Pharmaceutical Composition 2 – as for Example 1 above


5

Table 1: Summary of Median Serum Derived Pharmacokinetic Parameters for Pharmaceutical Compositions 1 and 2 of 2-(4-Ethoxy-phenyl)-3-(4-methanesulfonyl-phenyl)-pyrazolo[1,5-b]pyridazine from a Healthy Male Volunteer Study of 24 Subjects.

	AUC last (ng/mL.h)	T <sub>max</sub> (h)	C <sub>max</sub> (ng/mL)
Pharmaceutical Composition 1	492.16	1.75	72.39
Pharmaceutical Composition 2	840.13	1	152.33


10

Graph 1:




15

Graph 2:



5

Graph 3:




- 10 The application of which this description and these claims form a part may be used as a basis for priority in respect of any subsequent application. The claims of such subsequent application may be directed to any novel feature or combination of features relating to the invention as

described herein. They may take the form of a product, process or use claims and may include, by way of example and without limitation the claims that follow.

Claims

- 5 1. A pharmaceutical composition comprising compound (I)



and pharmaceutically acceptable salts thereof, in which the compound is present in solid particles in nanoparticulate form in admixture with one or more pharmaceutically acceptable carriers or excipients.

10

2. A pharmaceutical composition as claimed in claim 1 which further comprises HPMC present in less than 15% w/w.

15

3. A process for preparing a pharmaceutical composition according to any of claims 1 or 2 comprising wet milling a suspension of compound (I) in a mill having at least one chamber and agitation means, said chamber(s) and/or said agitation means comprising a lubricated nylon.

20


4. A method of treating a human or animal subject suffering from a condition which is mediated by selective inhibition of COX-2 which comprises administering a pharmaceutical composition as defined in any of claims 1 or 2.

25

5. The use of a pharmaceutical composition as defined in any of claims 1 or 2 for the manufacture of a medicament for the treatment of a condition which is mediated by selective inhibition of COX-2.

Abstract

The invention provides a pharmaceutical composition comprising a compound of formula (I)



5

and pharmaceutically acceptable salts thereof, in which the compound is present in solid particles in nanoparticulate form, in admixture with one or more pharmaceutically acceptable carriers or excipients.



**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**